{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:47:17Z","timestamp":1777956437757,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.path.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:37:14Z","timestamp":1773664634000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Twisted Tapestry of Tumors"],"prefix":"10.1016","volume":"19","author":[{"given":"Raza S.","family":"Hoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2026.01.005_bib1","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"issue":"7793","key":"10.1016\/j.path.2026.01.005_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"ITP-CAoWG","year":"2020","journal-title":"Nature"},{"issue":"7403","key":"10.1016\/j.path.2026.01.005_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"6797","key":"10.1016\/j.path.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib8","first-page":"491","article-title":"Lobular carcinoma in situ: a rare form of mammary cancer","volume":"17","author":"Foote","year":"1941","journal-title":"Am J Pathol"},{"key":"10.1016\/j.path.2026.01.005_bib9","series-title":"WHO classification of tumours: breast tumours","article-title":"Invasive lobular carcinoma","author":"Shin","year":"2019"},{"issue":"7","key":"10.1016\/j.path.2026.01.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100497","article-title":"Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the european lobular breast cancer consortium","volume":"37","author":"De Schepper","year":"2024","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib11","first-page":"987","article-title":"Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma","volume":"142","author":"Gamallo","year":"1993","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/path.2629","article-title":"The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type","volume":"220","author":"Weigelt","year":"2010","journal-title":"J Pathol"},{"issue":"16","key":"10.1016\/j.path.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","article-title":"Genomic characterization of primary invasive lobular breast cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41698-024-00508-x","article-title":"Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations","volume":"8","author":"Dopeso","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"15","key":"10.1016\/j.path.2026.01.005_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153695","article-title":"Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors","volume":"13","author":"Christgen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.path.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.1966.03100050096033","article-title":"Breast carcinoma in children","volume":"195","author":"McDivitt","year":"1966","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.path.2026.01.005_bib17","first-page":"8909","article-title":"The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1\/2 and PI3-kinase-Akt signaling for fibroblast transformation","volume":"61","author":"Tognon","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.path.2026.01.005_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.path.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.path.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/PAS.0000000000001366","article-title":"Pan-TRK immunohistochemistry: a useful diagnostic adjunct for secretory carcinoma of the breast","volume":"43","author":"Harrison","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.path.2026.01.005_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/his.13879","article-title":"Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential","volume":"75","author":"Hoda","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.path.2026.01.005_bib23","article-title":"Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma","volume":"2017doi","author":"Shukla","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2613","article-title":"Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study","volume":"12","author":"Ghabach","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000478-200204000-00002","article-title":"Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases","volume":"26","author":"Shin","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41379-021-00931-6","article-title":"The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features","volume":"35","author":"Schwartz","year":"2022","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/path.4573","article-title":"Genomic landscape of adenoid cystic carcinoma of the breast","volume":"237","author":"Martelotto","year":"2015","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/path.5006","article-title":"MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene","volume":"244","author":"Kim","year":"2018","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.path.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/PAS.0000000000000878","article-title":"MYB labeling by immunohistochemistry is more sensitive and specific for breast adenoid cystic carcinoma than MYB labeling by FISH","volume":"41","author":"Poling","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib30","first-page":"196","article-title":"Low-grade mucoepidermoid carcinoma of the breast","volume":"103","author":"Patchefsky","year":"1979","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.path.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-020-0164-0","article-title":"Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes","volume":"6","author":"Pareja","year":"2020","journal-title":"npj Breast Cancer"},{"issue":"3","key":"10.1016\/j.path.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/his.13779","article-title":"CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast","volume":"74","author":"Bean","year":"2019","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.path.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.humpath.2008.11.004","article-title":"Mucoepidermoid carcinoma of the breast shares cytogenetic abnormality with mucoepidermoid carcinoma of the salivary gland: a case report with molecular analysis and review of the literature","volume":"40","author":"Camelo-Piragua","year":"2009","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.path.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/00000478-200308000-00008","article-title":"Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases","volume":"27","author":"Eusebi","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"10.1016\/j.path.2026.01.005_bib35","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1158\/0008-5472.CAN-16-0298","article-title":"IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity","volume":"76","author":"Chiang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.path.2026.01.005_bib36","article-title":"Solid-papillary carcinoma with reverse polarity (SPCRP) harboring a novel IDH1 R132C mutation: a case confirming the expected IDH1\/IDH2 dichotomy","volume":"21","author":"Weisman","year":"2020","journal-title":"Hum Pathol: Case Reports"},{"issue":"6","key":"10.1016\/j.path.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41379-019-0442-2","article-title":"Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity","volume":"33","author":"Pareja","year":"2020","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000478-198604000-00002","article-title":"Is microglandular adenosis a precancerous disease? A study of carcinoma arising therein","volume":"10","author":"Rosenblum","year":"1986","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/modpathol.2016.161","article-title":"Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.path.2026.01.005_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100144","article-title":"NR4A3 expression is consistently absent in acinic cell carcinomas of the breast: a potential nosologic shift","volume":"36","author":"Richardson","year":"2023","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib41","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/path.4566","article-title":"The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study","volume":"237","author":"Guerini-Rocco","year":"2015","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.path.2026.01.005_bib42","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/modpathol.2017.57","article-title":"So-called acinic cell carcinoma of the breast arises from microgladular adenosis and is not a distinct entity","volume":"30","author":"Rosen","year":"2017","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.path.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ng.3037","article-title":"Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma","volume":"46","author":"Lim","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/path.5333","article-title":"Genomic characterisation of breast fibroepithelial lesions in an international cohort","volume":"249","author":"Md Nasir","year":"2019","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib45","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/path.4672","article-title":"Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression","volume":"238","author":"Piscuoglio","year":"2016","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.path.2026.01.005_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100593","article-title":"Targeted DNA sequencing in diagnosis of malignant phyllodes tumors with emphasis on tumors with keratin and p63 expression","volume":"37","author":"Ye","year":"2024","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.path.2026.01.005_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/gcc.22272","article-title":"Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis","volume":"54","author":"Crago","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2559.2007.02794.x","article-title":"Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature","volume":"51","author":"Carlson","year":"2007","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.path.2026.01.005_bib49","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/modpathol.2010.141","article-title":"beta-catenin\/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast","volume":"23","author":"Lacroix-Triki","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","author":"Desmoid Tumor","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.path.2026.01.005_bib51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH635>3.0.CO;2-R","article-title":"Myofibroblastoma of the breast: genetic link with spindle cell lipoma","volume":"191","author":"Pauwels","year":"2000","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.path.2026.01.005_bib52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2559.2007.02775.x","article-title":"Cellular angiofibroma: another mesenchymal tumour with 13q14 involvement, suggesting a link with spindle cell lipoma and (extra)-mammary myofibroblastoma","volume":"51","author":"Maggiani","year":"2007","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.path.2026.01.005_bib53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/PGP.0000000000000559","article-title":"Potential diagnostic pitfalls in evaluating immunohistochemistry for cervical myofibroblastomas","volume":"38","author":"Song","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/gcc.20827","article-title":"Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions","volume":"50","author":"Guo","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/modpathol.2011.134","volume":"25","author":"Mentzel","year":"2012","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.path.2026.01.005_bib56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.breast.2004.09.014","article-title":"A case of nodular fascitis of the breast and review of the literature","volume":"14","author":"Brown","year":"2005","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.path.2026.01.005_bib57","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41379-021-00844-4","article-title":"Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners","volume":"34","author":"Cloutier","year":"2021","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng0197-95","article-title":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma","volume":"15","author":"Simon","year":"1997","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.path.2026.01.005_bib59","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/sj.onc.1204426","article-title":"Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP)","volume":"20","author":"Simon","year":"2001","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.path.2026.01.005_bib60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.22663","article-title":"Dermatofibrosarcoma protuberans with a novel COL6A3-PDGFD fusion gene and apparent predilection for breast","volume":"57","author":"Dickson","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.path.2026.01.005_bib61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/10668969231204957","article-title":"Solitary fibrous tumor of breast and axilla: clinicopathological profile of five tumors with comparison of risk stratification models","volume":"32","author":"Hoda","year":"2024","journal-title":"Int J Surg Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.005_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.2509","article-title":"Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.path.2026.01.005_bib63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/modpathol.2013.164","article-title":"Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics","volume":"27","author":"Doyle","year":"2014","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-025-02049-y","article-title":"Palazestrant, a novel oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), in patients with ER+\/HER2- advanced or metastatic breast cancer: phase 1\/2 study results","volume":"27","author":"Hamilton","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"12","key":"10.1016\/j.path.2026.01.005_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188051","article-title":"Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer","volume":"10","author":"Sherman","year":"2025","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.path.2026.01.005_bib66","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMx170011","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.path.2026.01.005_bib68","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.path.2026.01.005_bib69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.path.2026.01.005_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-01054-6","article-title":"Therapeutic targeting of mismatch repair-deficient cancers","author":"Johannet","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.path.2026.01.005_bib71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.path.2026.01.005_bib72","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.path.2026.01.005_bib73","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41698-025-01045-x","article-title":"Genomic characterization of tumor mutational burden-high breast carcinomas","volume":"9","author":"Vougiouklakis","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.path.2026.01.005_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102204","article-title":"Redefining cancer of unknown primary: is precision medicine really shifting the paradigm?","volume":"97","author":"Olivier","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.path.2026.01.005_bib76","article-title":"Personalized therapy selection by integration of molecular cancer classification by the 92-Gene assay and tumor profiling in patients with cancer of unknown primary","volume":"8","author":"Fuentes Bayne","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.005_bib77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40291-023-00650-5","article-title":"Validation of a transcriptome-based assay for classifying cancers of unknown primary origin","volume":"27","author":"Michuda","year":"2023","journal-title":"Mol Diagn Ther"},{"issue":"9","key":"10.1016\/j.path.2026.01.005_bib78","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1158\/2767-9764.CRC-25-0171","article-title":"GPSai: a clinically validated AI tool for tissue of origin prediction during routine tumor profiling","volume":"5","author":"Ghani","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.path.2026.01.005_bib79","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2019.3985","article-title":"Development of genome-derived tumor type prediction to inform clinical cancer care","volume":"6","author":"Penson","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187591812600005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187591812600005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:24:08Z","timestamp":1777947848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187591812600005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S187591812600005X"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2026.01.005","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twisted Tapestry of Tumors","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}